Alvotech
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ALVO | ALM.MC | AQST | ALKS | B6E.F | SOLARA.NS | |
|---|---|---|---|---|---|---|
| Market cap | 1.67B | 2.46B | 476.94M | 7.71B | 15.44B | 31.04B |
| P/E (TTM) | — | 34.3 | — | — | 25.6 | 83.4 |
| Forward P/E | 20.3 | 21.3 | -6.7 | 25.4 | — | 20.5 |
| Price/book | -8.7 | 1.6 | -13.8 | 4.2 | 0.4 | 2.2 |
| Dividend yield | — | 1.68% | — | — | — | — |
| 1-year change | −6.97% | −8.09% | −35.33% | +47.06% | +43.32% | +2.04% |
| Today | +2.86% | +1.80% | −2.06% | +0.44% | +1.98% | −0.25% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All ALVO news ›Alvotech (ALVO) Projected to Announce Quarterly Earnings on Wednesday
Posted by Michael Walen on Nov 4th, 2026 NASDAQ:ALVO opened at $4.54 on Wednesday. Alvotech has a 1-year low of $2.94 and a 1-year high of $6.53. The firm has a fifty day simple moving average of $5.30 and a 200 day simple moving average…
Alvotech: The Market Is Still Pricing The Broken Factory
Alvotech Stock: The Market Is Still Pricing The Broken Factory (NASDAQ:ALVO) Seeking Alpha - Alvotech is transitioning from supply remediation to throughput, with FDA-cleared facilities and multiple key biosimilar filings advancing toward…
Alvotech (NASDAQ:ALVO) & Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Head to Head Survey
Posted by Defense World Staff on Oct 26th, 2026 Alvotech (NASDAQ:ALVO – Get Free Report) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will…
Alvotech (NASDAQ:ALVO) Upgraded to “Hold” at Wall Street Zen
Posted by Mitch Edgeman on Oct 25th, 2026 Wall Street Zen upgraded shares of Alvotech (NASDAQ:ALVO – Free Report) from a sell rating to a hold rating in a report published on Saturday,Wall Street Zen reports. Check Out Our Latest Stock…
Alcon acquires Neurotech, MacTel therapy Encelto
Alcon, Inc. has purchased Neurotech Pharmaceuticals, Inc., developer of the first and only FDA-approved treatment for Macular Telangiectasia Type 2 (MacTel). Alcon shared two details surrounding the transaction: Headquartered in…
Alcon acquires Neurotech Pharmaceuticals
Alcon has acquired Neurotech Pharmaceuticals and Encelto, its macular telangiectasia type 2 therapy, according to a press release. Alcon paid $550 million in the acquisition of Neurotech and could make contingent payments based on…
More from 1 other outlet
Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2
Alcon | United States Alcon United States is only available in English. Click below to select a different location. GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly,…
Alvotech wins FDA approval to more than double SIMLANDI batch output
The Oct. 20 announcement says the process frees capacity for other biosimilars but gives no implementation date or quantified unit-cost savings. More than twice as much SIMLANDI drug substance can be produced per batch after Alvotech…
Alvotech: SIMLANDI output per batch more than doubles
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania Fort Technology: Logia USA Signs Exclusive Distribution Agreement to Expand Fuel Maintenance Solutions for Data…
Alvotech And Advanz Pharma Holdco Limited Submit European Regulatory Application For AVT29, Proposed Biosimilar To Eylea 8 Mg
Alvotech and Advanz Pharma announced the submission of a European regulatory application for AVT29, a proposed biosimilar to Eylea® 8 mg , which is marketed as Eylea HD® in the United States. Based... Alvotech and Advanz Pharma announced…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com11
- stocktitan.net8
- quiverquant.com5
- globenewswire.com4
- manilatimes.net4
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 69 articles, not a forecast.